Suppliers and packagers for travoprost

travoprost

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	210458	ANDA	Alembic Pharmaceuticals Inc.	62332-510-05	1 BOTTLE in 1 CARTON (62332-510-05) / 5 mL in 1 BOTTLE	2019-12-20
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	210458	ANDA	Alembic Pharmaceuticals Inc.	62332-510-25	1 BOTTLE in 1 CARTON (62332-510-25) / 2.5 mL in 1 BOTTLE	2019-12-20
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	214687	ANDA	Alembic Pharmaceuticals Limited	46708-625-02	1 BOTTLE in 1 CARTON (46708-625-02) / 2.5 mL in 1 BOTTLE	2025-12-17
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	214687	ANDA	Alembic Pharmaceuticals Limited	46708-625-05	1 BOTTLE in 1 CARTON (46708-625-05) / 5 mL in 1 BOTTLE	2025-12-17
Alembic	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	214687	ANDA	Alembic Pharmaceuticals Inc.	62332-625-02	1 BOTTLE in 1 CARTON (62332-625-02) / 2.5 mL in 1 BOTTLE	2025-12-17

TRAVOPROST SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report details the supplier landscape for travoprost, a prostaglandin analog used to treat glaucoma and ocular hypertension. Key suppliers of the active pharmaceutical ingredient (API) and intermediates are identified, alongside their regulatory status and geographical distribution. The analysis includes patent expiration dates relevant to travoprost and potential market entry for generic manufacturers.

What is Travoprost and its Market Significance?

Travoprost is a synthetic prostamide analogue that functions as a prostaglandin F2α receptor agonist. Its primary therapeutic application is reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By increasing uveoscleral outflow of aqueous humor, travoprost effectively lowers IOP, a critical factor in preventing optic nerve damage and vision loss.

The global glaucoma treatment market is substantial and projected to grow. Travoprost, as a widely prescribed medication, holds a significant share of this market. Its efficacy, established safety profile, and availability in various formulations contribute to its sustained demand. The genericization of travoprost has led to increased accessibility and competition, further influencing market dynamics and supply chain considerations.

Key Active Pharmaceutical Ingredient (API) Suppliers for Travoprost

The production of travoprost API involves complex multi-step synthesis. Several manufacturers globally are recognized for their capabilities in producing high-quality travoprost API that meets stringent pharmacopeial standards. These suppliers are crucial for both branded and generic drug manufacturers.

Supplier Name	Country of Origin	Regulatory Approvals (e.g., US FDA, EMA)	Notes
Siegfried AG	Switzerland	US FDA, EMA	A leading global contract development and manufacturing organization.
Piramal Pharma Solutions	India	US FDA, EMA	Offers comprehensive API development and manufacturing services.
Divi's Laboratories	India	US FDA, EMA	Specializes in generic APIs with a strong focus on quality.
LGM Pharma	United States	US FDA	A supplier and distributor of APIs, focusing on regulated markets.
Amoli Organics Pvt. Ltd.	India	US FDA, EMA	Manufactures a range of APIs, including ophthalmological agents.
Centrient Pharmaceuticals	Netherlands	US FDA, EMA	Known for its expertise in antibiotic and other APIs.
Rhodia S.A. (now Solvay)	France	N/A (API production)	Historically a significant supplier; current status requires verification.
Takeda Pharmaceutical Company	Japan	N/A (API production)	May supply through internal manufacturing or contract entities.

The regulatory approvals listed are indicative and may require specific site inspections or certifications for individual drug product applications. The presence of US FDA and EMA approvals signifies a higher level of scrutiny and quality assurance, essential for supplying to major pharmaceutical markets.

Intermediates and Key Starting Materials

The synthesis of travoprost requires several complex intermediates. Ensuring a stable and cost-effective supply of these precursors is vital for API manufacturers. The supply chain for these intermediates often extends to specialized chemical manufacturers.

Key intermediates and starting materials include, but are not limited to:

• Prostaglandin F2α derivatives: These form the core structure of travoprost.
• Chiral building blocks: Travoprost is a chiral molecule, necessitating precise stereoselective synthesis.
• Specialty reagents: Specific catalysts and reagents are required for various reaction steps.

Geographically, intermediate suppliers are often concentrated in regions with strong chemical manufacturing infrastructure, such as China and India, alongside specialized producers in Europe and North America. A robust supply chain for intermediates mitigates risks associated with single-source dependency and geopolitical instability.

Travoprost Patent Landscape and Generic Entry

Understanding the patent status of travoprost is critical for assessing market exclusivity and the potential for generic competition. The primary patent covering travoprost itself has expired in major markets, paving the way for generic manufacturers.

• US Patent 5,352,707: This foundational patent, covering travoprost, expired in 2014. This date marked the potential for generic entry in the United States.
• European Patent EP0655424B1: Similar to the US, the patent protection for travoprost in Europe has expired, allowing for generic formulations to be marketed.

While the core composition-of-matter patents have expired, other patents may exist covering specific formulations, polymorphs, manufacturing processes, or methods of use. Generic companies must conduct thorough freedom-to-operate (FTO) analyses to ensure their products do not infringe on any remaining valid patents.

Key implications of patent expiration:

• Increased competition: Multiple generic versions of travoprost eye drops have entered the market.
• Price erosion: Competition typically leads to significant price reductions for the drug.
• Supply chain diversification: Generic manufacturers may seek multiple API suppliers to ensure competitive pricing and supply security.

The initial innovator, often under brands like Travatan, faces reduced market share and revenue post-patent expiry. The focus for these companies then shifts to next-generation products or maintaining market presence through established brand recognition and distribution networks.

Regulatory Considerations for Travoprost Suppliers

Suppliers of travoprost API and intermediates must adhere to strict regulatory guidelines. Compliance with Current Good Manufacturing Practices (cGMP) is paramount. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others worldwide conduct inspections to ensure adherence to quality and safety standards.

Key regulatory requirements include:

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and facilities used for API production. Drug product manufacturers can then reference these DMFs in their marketing authorization applications.
• Impurity profiling: Rigorous analysis and control of impurities are essential. This includes genotoxic impurities and process-related impurities.
• Stability studies: Comprehensive data demonstrating the stability of the API under various storage conditions is required.
• Audits and inspections: Regular audits by customers (drug product manufacturers) and inspections by regulatory authorities are standard.

The ability of a supplier to maintain these regulatory standards directly impacts their market access and the trust placed in them by pharmaceutical companies. Suppliers with a history of successful regulatory inspections and well-maintained DMFs are generally preferred.

Geographical Distribution of Travoprost Suppliers

The global supply chain for travoprost is geographically diverse, with significant manufacturing hubs in Asia, Europe, and North America. This distribution offers advantages in terms of cost, expertise, and risk mitigation.

• India: A major hub for API and intermediate manufacturing, known for its cost-effectiveness and large-scale production capabilities. Many suppliers here have established strong relationships with global pharmaceutical companies and hold US FDA and EMA approvals.
• China: A significant producer of chemical intermediates and some APIs. While cost-effective, regulatory oversight and quality consistency can be variable, requiring due diligence.
• Europe: Hosts a number of established API manufacturers, particularly in Switzerland and Germany, known for high quality and advanced manufacturing technologies. These suppliers often command premium pricing.
• United States: Features specialized API manufacturers and contract development and manufacturing organizations (CDMOs) that focus on complex molecules and regulated markets.

The diversification of suppliers across these regions helps to build resilience against supply chain disruptions, whether caused by geopolitical events, natural disasters, or trade disputes.

Challenges and Risks in the Travoprost Supply Chain

Despite the maturity of the travoprost market, several challenges and risks persist within its supply chain.

• Quality control and consistency: Maintaining consistent quality across different batches and suppliers is an ongoing challenge, especially with complex synthetic routes.
• Regulatory changes: Evolving regulatory requirements and increasing scrutiny on impurity control can necessitate significant investment in process upgrades for suppliers.
• Intellectual property: While core patents have expired, ongoing litigation or the emergence of new patents related to specific manufacturing processes or formulations can create uncertainty.
• Geopolitical and economic factors: Trade policies, tariffs, currency fluctuations, and political instability in key manufacturing regions can impact costs and availability.
• Environmental regulations: Increasingly stringent environmental regulations in chemical manufacturing can lead to increased operating costs and potential supply disruptions for non-compliant facilities.
• Supply chain security: Ensuring the integrity and security of the supply chain against counterfeiting or diversion is critical, particularly for ophthalmic drugs.

Proactive risk management strategies, including dual sourcing, robust quality agreements with suppliers, and continuous monitoring of the regulatory and geopolitical landscape, are essential for pharmaceutical companies.

Key Takeaways

• The travoprost API market is served by a diversified global supplier base, with India, Europe, and North America being key manufacturing regions.
• Major API suppliers possess US FDA and EMA regulatory approvals, indicating adherence to stringent quality standards.
• The patent landscape for travoprost has largely expired, enabling generic competition and influencing supply chain dynamics towards cost-efficiency and multiple sourcing strategies.
• A stable supply of critical intermediates is essential, with manufacturers often sourcing from specialized chemical producers in Asia and Europe.
• Regulatory compliance, particularly cGMP and DMF submission, is a non-negotiable requirement for API suppliers.
• Risks include quality consistency, evolving regulations, geopolitical instability, and environmental compliance, necessitating robust supply chain management.

Frequently Asked Questions

1. Who are the primary generic API suppliers for travoprost? Indian manufacturers like Divi's Laboratories and Amoli Organics are significant players, alongside European and North American CDMOs.

2. What are the key intermediates required for travoprost synthesis? These include prostaglandin F2α derivatives and specific chiral building blocks, sourced from specialty chemical manufacturers.

3. When did the primary patent for travoprost expire in the US and Europe? The US patent expired in 2014, and European patent protection has also lapsed.

4. What is the typical regulatory filing for an API supplier? API suppliers typically file Drug Master Files (DMFs) with regulatory agencies like the US FDA and EMA.

5. How does the expiry of travoprost patents affect API suppliers? Patent expiry leads to increased demand from generic drug manufacturers and often intensifies competition among API suppliers, driving a focus on cost-effectiveness and supply reliability.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Patent Term Restoration Information. FDA. [2] European Patent Office. (n.d.). Espacenet. EPO. [3] Siegfried AG. (n.d.). Siegfried. [4] Piramal Pharma Solutions. (n.d.). Piramal Pharma Solutions. [5] Divi's Laboratories. (n.d.). Divi's Laboratories. [6] LGM Pharma. (n.d.). LGM Pharma. [7] Amoli Organics Pvt. Ltd. (n.d.). Amoli Organics. [8] Centrient Pharmaceuticals. (n.d.). Centrient Pharmaceuticals. [9] Solvay S.A. (n.d.). Solvay. [10] Takeda Pharmaceutical Company. (n.d.). Takeda.